Woburn, Massachusetts-based HD LifeSciences, LLC has named financial professional Tim Jette its chief financial officer.
HD LifeSciences Names Tim Jette Chief Financial Officer
1 min read Premium comments
Secondary#hdlifesciences#timjette
Jette has notable experience in the medical technology industry. After receiving his Master of Business Administration degree from Chicago, Illinois-based University of Chicago Booth Graduate School of Business, he joined Medtronic as a finance manager and analyst.
Jette spent more than 25 years working at Medtronic in roles of increasing responsibility. In his most recent position, he served as chief financial officer of the Americas Cardiac and Vascular Group. He helped to scale the organization to achieve growth from $4.1 billion to $6 billion. Prior to that position, he served as chief financial officer of the Global Structural Heart Business where he helped scale business from $600 million to $1 billion.
Jette expressed excitement about his new position. He told OTW, “I’m excited to join the team at HD LifeSciences as we begin to scale our innovative technology within the spinal market.”
HD LifeSciences develops “3D printed spinal interbody fusion implants and instrumentation.” Its product portfolio includes cervical implants, transforaminal lumbar interbody fusion (TLIF) implants, and anterior lumbar interbody fusion (ALIF) implants. According to the company’s press release, its “Hive™ portfolio of interbody fusion devices provide surgeons and their patients ideal biomechanical elastic modulus properties, clear and precise diagnostic imaging capability, osteoblast cell attraction and integration.”
HD LifeSciences President and CEO Patrick O’Donnell said of Jette’s appointment, “We are very pleased to welcome Tim [Jette] to our growing team of industry veterans. I’m particularly excited to have a talented and experienced partner as we embark upon raising growth capital to drive our next stages of value building and commercial growth for our innovative Hive™ portfolio of 3D printed titanium interbody products.”
O’Donnell joined HD LifeSciences earlier this year. For OTW’s coverage, see “HD LifeSciences Names Patrick O’Donnell President and CEO.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.